Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
Biomark Med. 2019 Jun;13(9):761-771. doi: 10.2217/bmm-2018-0441. Epub 2019 Jun 3.
p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV hybridization were analyzed. p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.
p16 和 p53 是癌症中经常发生改变的细胞内途径。我们研究了原发性非小细胞肺癌中 p16 的异常表达及其与 p53 和 HPV 状态的关系。对肺肿瘤组织微阵列（n=163）进行了 p16 和 p53 的免疫组织化学研究，并进行了 HPV 杂交分析。p16 和 p53 在腺癌（ADCs；n=75）中分别检测到 50.7%和 57.3%，在鳞状细胞癌（n=88）中分别检测到 35.2%和 63.6%。HPV 在 ADC 和鳞状细胞癌中分别检测到 16%和 10.2%。在 ADC 中，p16 阳性肿瘤的中位总生存时间为 60.9 个月，而 p16 阴性肿瘤为 46.9 个月（p<0.05）。此外，我们没有发现 p16 表达与 HPV 状态之间以及与 p53 表达之间存在显著关系。p16 在肺癌的生存中发挥了独特的作用。需要进一步研究 p16 的作用机制。
